Riluzole likely lacks antidepressant efficacy in ketamine non-responders

Mark J Niciu, David A Luckenbaugh, Dawn F Ionescu, Erica M Richards, Jennifer L Vande Voort, Elizabeth D Ballard, Nancy E Brutsche, Maura L Furey, Carlos A Zarate Jr, Mark J Niciu, David A Luckenbaugh, Dawn F Ionescu, Erica M Richards, Jennifer L Vande Voort, Elizabeth D Ballard, Nancy E Brutsche, Maura L Furey, Carlos A Zarate Jr

No abstract available

Keywords: Glutamate; Ketamine; Major depressive disorder; Riluzole; Treatment-resistant depression.

Conflict of interest statement

Conflict of interest

Drs. Niciu, Ionescu, Richards, Vande Voort, Ballard, Ms. Brutsche and Mr. Luckenbaugh have no potential financial conflicts of interest to disclose. Dr. Furey is listed as a co-inventor on a patent application for the use of scopolamine in major depression, and Dr. Zarate is listed as a co-inventor on a patent application for the use of ketamine and its metabolites in major depression. Drs. Furey and Zarate have assigned their rights in the patent to the U.S. Government but will share a percentage of any royalties that may be received by the Government.

Figures

Fig. 1

Riluzole Appears to Lack Antidepressant Efficacy in Ketamine Non-Responders. On randomization to flexible dose riluzole (100–200 mg/day) or placebo 4–6 h after a single open-label subanesthetic dose (0.5 mg/kg) ketamine infusion, there was no difference in antidepressant efficacy over the ensuing four weeks in ketamine non-responders (as defined by F(27,231) = 1.15, p = .29], Abbreviations: TRD: treatment-resistant major depressive disorder.